Results 251 to 260 of about 756,046 (308)

Mapping drug mechanisms with ProteomicsDB: unified omics and cell sensitivity data at scale. [PDF]

Nucleic Acids Res
Picciani M, Soleymaniniya A, Müller J, Sakhteman A, Tzanakis K, Bernett J, Kahl E, Hamood F, Kersting J, Pourjam M, Nagai LAE, List M, Kuster B, The M, Wilhelm M.   +14 more
europepmc   +1 more source

Fast‐Responding O2 Gas Sensor Based on Luminescent Europium Metal‐Organic Frameworks (MOF‐76)

Advanced Functional Materials, EarlyView.
Luminescent MOF‐76 materials based on Eu(III) and mixed Eu(III)/Y(III) show rapid and reversible changes in emission intensity in response to O2 with very short response times. The effect is based on triplet quenching of the linker ligands that act as photosensitizers. Average emission lifetimes of a few milliseconds turn out to be mostly unaffected by
Zhenyu Zhao, Christian Weinberger, Jakob Steube, Matthias Bauer, Martin Brehm, Michael Tiemann   +5 more
wiley   +1 more source

Comparative gastrointestinal effects of antidepressants for the acute treatment of adults with major depressive disorder: a network and dose‒response meta-analysis. [PDF]

Transl Psychiatry
Wen S, Yan Y, Shao J, Xie H, Wang M, Dou Y, Liu D, Yang X, Ma X.   +8 more
europepmc   +1 more source

Optimizing Anti-PD1 Immunotherapy: An Overview of Pharmacokinetics, Biomarkers, and Therapeutic Drug Monitoring. [PDF]

Cancers (Basel)
Monteiro JF, Fernandes A, Tato DG, Moreira E, Ribeiro R, Reguengo H, Gonçalves J, Fresco P.   +7 more
europepmc   +1 more source

FDA-AACR Strategies for Optimizing Dosages for Oncology Drug Products: Early-Phase Trials Using Innovative Trial Designs and Biomarkers. [PDF]

Clin Cancer Res
Okusanya OO, Patilea-Vrana GI, Sireci A, Iasonos A, Davidson BA, Liu J, Shord SS, LoRusso PM, Yap TA.   +8 more
europepmc   +1 more source

Towards new approach methodologies for biological therapeutics: a novel model-informed metric to assess immunogenicity risk. [PDF]

Front Immunol
Rose RH, Shuaib A, Wigbers M, Khalifa M, Kierzek AM, van der Graaf PH.   +5 more
europepmc   +1 more source

Personalizing Antidepressant Therapy: Integrating Pharmacogenomics, Therapeutic Drug Monitoring, and Digital Tools for Improved Depression Outcomes. [PDF]

J Pers Med
Parshenkov M, Zyryanov S, Rodionova G, Dyakonova A, Shegay P, Kaprin A, Demyashkin G.   +6 more
europepmc   +1 more source

Using Dose-Response Correlation Re-Analyzing to Distinguish Placebo from Standardized Rose-Hip Powder (Lito) in a Clinical Trial on Osteoarthritis Where Data Initially Looked Identical. [PDF]

Nutrients
Motawei AM, Warholm KM, Winther K.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Dose‐response relationship characterization in current anti‐hypertensive drug development

Clinical Pharmacology & Therapeutics, 2003
Clinical Pharmacology & Therapeutics (2003) 73, P68–P68; doi:
J. V. Gobburu, R. J. Lipicky
openaire   +1 more source

An Alternate Method for Estimating the Dose-Response Relationships of Neuromuscular Blocking Drugs

Anesthesia & Analgesia, 2000
Slopes of the dose-response relationships for all available neuromuscular blocking drugs appear to be essentially parallel and to approximate a log-dose/logit value of 4.75. We tested the possibility of estimating both 50% effective dose (ED(50)) and 95% effective dose (ED(95)) values from a single dose-response data point when that slope is postulated.
A F, Kopman, M M, Klewicka, G G, Neuman
openaire   +2 more sources